Commentary on Twitter (thread – click for more)
The Technical Advisory Group on SARS-CoV-2 Virus Evolution met today to review what is known about the #COVID19 variant B.1.1.529.
They advised WHO that it should be designated a Variant of Concern.
WHO has named it Omicron, in line with naming protocols https://t.co/bSbVas9yds pic.twitter.com/Gev1zIt1Ek
— World Health Organization (WHO) (@WHO) November 26, 2021
- Omicron: What we know so far about the new COVID-19 variant | DW News
- OMG Omicron? | A Doctor Explains, LIVE – ZDoggMD
[Press release – not published yet] Merck’s new Covid-19 pill Molnupiravir updated data shows reduced efficacy (30%) for preventing hospitalization and death compared to initial results (50%). Absolute risk reduction of hospitalization and death fell from 7% to 3%.28 Nov, 2021 | 21:30h | UTC
News Release: Merck and Ridgeback Biotherapeutics Provide Update on Results from MOVe-OUT Study of Molnupiravir, an Investigational Oral Antiviral Medicine, in At Risk Adults With Mild-to-Moderate COVID-19
[Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19.
Commentaries on Twitter
💥Merck Provides Update on Results from MOVe-OUT Study of Molnupiravir, an Investigational Oral Antiviral Medicine, in At Risk Adults With Mild-to-Moderate COVID-19
RRR fell from 50% to 30%
Absolute Risk reduction only 3% #IDTwitter https://t.co/aX2b3xrdnB pic.twitter.com/uXUSQRNWC7
— Antibiotic Stewa®️x🆔 Bassam Ghanem (@ABsteward) November 26, 2021
Disappointing from Merck. Updated data for efficacy of their Molnupiravir pill in full trial drops down to 30% from 50%, absolute reduction to 3 from 7 per 100 at interim analysis https://t.co/PyfIBnFNC7 pic.twitter.com/SBDL92aG5M
— Eric Topol (@EricTopol) November 26, 2021
Commentary on Twitter
Pandemic treaty decision: "I think…there's enough support to begin negotiations over a legally binding agreement", @LawrenceGostin tells The Lancet.@jzarocostas reports from Geneva ahead of a Special Session of the World Health Assembly. https://t.co/rKdbPi8Bwo
— The Lancet (@TheLancet) November 27, 2021
Commentary on Twitter
‼️ EMA recommends approval of BioNTech/Pfizer’s #COVID19vaccine, Comirnaty, for children aged 5 to 11.
In this population, the dose of #Comirnaty will be lower than that used in people aged 12 and above.
— EU Medicines Agency (@EMA_News) November 25, 2021
Heavily mutated coronavirus variant puts scientists on alert – “Researchers are racing to determine whether a fast-spreading variant in South Africa poses a threat to COVID vaccines’ effectiveness”.26 Nov, 2021 | 08:42h | UTC
Related commentary on Twitter (thread – click for more)
THREAD on the new variant B.1.1.529 summarising what is known from the excellent South African Ministry of Health meeting earlier today
TLDR: So much uncertain but what *is* known is extremely worrying & (in my opinion) we should revise red list immediately.
This is why: 1/16
— Prof. Christina Pagel (@chrischirp) November 25, 2021
Commentary from the author on Twitter
VAX THE WORLD!
is our wish/plea on #Thanksgiving day
— Madhu Pai, MD, PhD (@paimadhu) November 25, 2021
Commentary from the author on Twitter (thread – click for more)
1/ Our preprint on #SARSCoV2 antibody responses in UK adults receiving a #COVID19 vaccine booster with the Pfizer vaccine at least 6 months after primary immunisation with Pfizer or AZ vaccine, which was given at an extended interval (8-12 wks) … 🧵
— Shamez Ladhani (@ShamezLadhani) November 25, 2021
A population-based cohort study in Qatar showed reinfections had 90% lower odds of resulting in hospitalization or death than primary infections.25 Nov, 2021 | 10:46h | UTC
Perspective: COVID-19 vaccine makers plan for annual boosters, but it’s not clear they’ll be needed.25 Nov, 2021 | 10:43h | UTC
Do vaccines protect against long COVID? What the data say – “Vaccines reduce the risk of developing COVID-19 — but studies disagree on their protective effect against long COVID”.25 Nov, 2021 | 10:41h | UTC
Provocative study suggests that persistent physical symptoms after COVID-19 infection may be associated more with the belief in having been infected with SARS-CoV-2 than with having laboratory-confirmed COVID-19 infection.
M-A: More than 50 long-term effects of COVID-19. (several articles on the subject)
Commentary on Twitter
Vaccines reduce the risk of long COVID by lowering the chances of contracting COVID-19. But studies suggest that vaccination might only halve the risk of long COVID, or have no effect on it at all, in a breakthrough infection. Read the @Nature report. https://t.co/MEkzXyO7hD
— Nature Portfolio (@NaturePortfolio) November 25, 2021
WHO issues guidelines on the treatment of children with multisystem inflammatory syndrome associated with COVID-19.24 Nov, 2021 | 08:51h | UTC
Cohort study: Among children with Multisystem Inflammatory Syndrome (MIS-C) associated with Covid-19, there was no evidence that recovery differed after primary treatment with intravenous immune globulin (IVIG) alone, IVIG plus glucocorticoids, or glucocorticoids alone.
Cohort study: Among children with Multisystem Inflammatory Syndrome (MIS-C) associated with Covid-19, initial treatment with intravenous immune globulin (IVIG) plus glucocorticoids was associated with a lower risk of new or persistent cardiovascular dysfunction than IVIG alone.
Cohort study showed that the incidence of Multisystem Inflammatory Syndrome in Children (MIS-C) was 316 persons per 1 000 000 SARS-CoV-2 infections in persons younger than 21 years. The incidence was higher among Black, Hispanic or Latino, and Asian or Pacific Islander persons.
Observational study: The combination of Immunoglobulins + Methylprednisolone was associated with a better course of fever compared to Immunoglobulins alone in Multisystem Inflammatory Syndrome in children
New systematic review of Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 infection summarizes the clinical features, management, and outcomes of the disease, showing favorable outcomes for the majority of children
Opinion from thirty two ministers of health: The world must act now to be prepared for future health emergencies.24 Nov, 2021 | 08:49h | UTC
Commentary on Twitter
Solidarity is key to protect the world from pandemics. This call by over 30 governments for a #PandemicTreaty to prepare for & respond to pandemics shows collaboration at work. The upcoming #WHASpecial session is a historic opportunity to make the world safer. https://t.co/98TgPce03t
— Tedros Adhanom Ghebreyesus (@DrTedros) November 23, 2021
Promoting COVID-19 vaccine acceptance: recommendations from the Lancet Commission on Vaccine Refusal, Acceptance, and Demand in the USA.24 Nov, 2021 | 08:47h | UTC
[Preprint] Systematic Review: Duration of Effectiveness of Vaccines Against SARS-CoV-2 Infection and COVID-19 Disease – “effectiveness against COVID-19 severe disease remained high (>70%) in most studies in the six months after full vaccination, although it did decrease some (on average, 8-10 percentage points) between one and six months after full vaccination”.23 Nov, 2021 | 08:57h | UTC
[Preprint] Breakthrough SARS-CoV-2 infections in 620,000 U.S. Veterans, February 1, 2021 to August 13, 2021 – “Vaccine protection declined by mid-August 2021, decreasing from 91.9% in March to 53.9%”.
Observational study in Qatar showed the effectiveness of Pfizer vaccine against any SARS-CoV-2 infection dropped to 20% in months 5 through 7 after the second dose, but effectiveness against severe Covid-19 remained high.
Cohort study: Pfizer vaccine effectiveness against any infections declined from 88% during the first month after full vaccination to 47% after 5 months. Vaccine effectiveness against hospital admissions remained high; 87% within 1 month, and 88% at 5 months after full vaccination, with no significant waning.
Populational study in France did not show an increased incidence of acute myocardial infarction, stroke, and pulmonary embolism following the Pfizer vaccine.23 Nov, 2021 | 08:51h | UTC
United States FDA clears COVID vaccine boosters for all adults over 18 – Pfizer & Moderna 6 months after second jab.21 Nov, 2021 | 23:17h | UTC
Estimation of SARS-CoV-2 infection fatality rate by age and comorbidity status using antibody screening of blood donors during the COVID-19 epidemic in Denmark – “The IFR was low for people younger than 51 years without comorbidity during the two waves (combined IFR = 3.36 per 100,000 infections)”.21 Nov, 2021 | 23:12h | UTC
Commentary on Twitter
New in JID: A study in Denmark found that the SARS-CoV-2 infection fatality rate was low for people younger than 51 and otherwise healthy, increased with age and comorbidities, and declined from the 1st to the 2nd wave of the pandemic.
— IDSA (@IDSAInfo) November 20, 2021